Pauline Désogère1,2, Luis F Tapias3, Tyson A Rietz1, Nicholas Rotile1, Francesco Blasi1, Helen Day1, Justin Elliott3, Bryan C Fuchs4, Michael Lanuti3, Peter Caravan5,2. 1. The Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts. 2. The Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 3. Division of Thoracic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; and. 4. Division of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 5. The Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts caravan@nmr.mgh.harvard.edu.
Abstract
There is a large unmet need for a simple, accurate, noninvasive, quantitative, and high-resolution imaging modality to detect lung fibrosis at early stage and to monitor disease progression. Overexpression of collagen is a hallmark of organ fibrosis. Here, we describe the optimization of a collagen-targeted PET probe for staging pulmonary fibrosis. Methods: Six peptides were synthesized, conjugated to a copper chelator, and radiolabeled with 64Cu. The collagen affinity of each probe was measured in a plate-based assay. The pharmacokinetics and metabolic stability of the probes were studied in healthy rats. The capacity of these probes to detect and stage pulmonary fibrosis in vivo was assessed in a mouse model of bleomycin-induced fibrosis using PET imaging. Results: All probes exhibited affinities in the low micromolar range (1.6 μM < Kd < 14.6 μM) and had rapid blood clearance. The probes showed 2- to 8-fold-greater uptake in the lungs of bleomycin-treated mice than sham-treated mice, whereas the distribution in other organs was similar between bleomycin-treated and sham mice. The probe 64Cu-CBP7 showed the highest uptake in fibrotic lungs and the highest target-to-background ratios. The superiority of 64Cu-CBP7 was traced to a much higher metabolic stability compared with the other probes. The specificity of 64Cu-CBP7 for collagen was confirmed by comparison with a nonbinding isomer. Conclusion: 64Cu-CBP7 is a promising candidate for in vivo imaging of pulmonary fibrosis.
There is a large unmet need for a simple, accurate, noninvasive, quantitative, and high-resolution imaging modality to detect lung fibrosis at early stage and to monitor disease progression. Overexpression of collagen is a hallmark of organ fibrosis. Here, we describe the optimization of a collagen-targeted PET probe for staging pulmonary fibrosis. Methods: Six peptides were synthesized, conjugated to a copper chelator, and radiolabeled with 64Cu. The collagen affinity of each probe was measured in a plate-based assay. The pharmacokinetics and metabolic stability of the probes were studied in healthy rats. The capacity of these probes to detect and stage pulmonary fibrosis in vivo was assessed in a mouse model of bleomycin-induced fibrosis using PET imaging. Results: All probes exhibited affinities in the low micromolar range (1.6 μM < Kd < 14.6 μM) and had rapid blood clearance. The probes showed 2- to 8-fold-greater uptake in the lungs of bleomycin-treated mice than sham-treated mice, whereas the distribution in other organs was similar between bleomycin-treated and sham mice. The probe 64Cu-CBP7 showed the highest uptake in fibrotic lungs and the highest target-to-background ratios. The superiority of 64Cu-CBP7 was traced to a much higher metabolic stability compared with the other probes. The specificity of 64Cu-CBP7 for collagen was confirmed by comparison with a nonbinding isomer. Conclusion:64Cu-CBP7 is a promising candidate for in vivo imaging of pulmonary fibrosis.
Authors: Zhaoda Zhang; Andrew F Kolodziej; Jianfeng Qi; Shrikumar A Nair; Xifang Wang; April W Case; Matthew T Greenfield; Philip B Graham; Thomas J McMurry; Peter Caravan Journal: New J Chem Date: 2010-02-12 Impact factor: 3.591
Authors: Francesco Blasi; Bruno L Oliveira; Tyson A Rietz; Nicholas J Rotile; Helen Day; Richard J Looby; Ilknur Ay; Peter Caravan Journal: J Nucl Med Date: 2014-05-01 Impact factor: 10.057
Authors: Christian T Farrar; Danielle K DePeralta; Helen Day; Tyson A Rietz; Lan Wei; Gregory Y Lauwers; Boris Keil; Arun Subramaniam; Anthony J Sinskey; Kenneth K Tanabe; Bryan C Fuchs; Peter Caravan Journal: J Hepatol Date: 2015-05-25 Impact factor: 25.083
Authors: Patrick A Helm; Peter Caravan; Brent A French; Vincent Jacques; Luhua Shen; Yaqin Xu; Ronald J Beyers; R Jack Roy; Christopher M Kramer; Frederick H Epstein Journal: Radiology Date: 2008-04-10 Impact factor: 11.105
Authors: Alison E John; Jeni C Luckett; Amanda L Tatler; Ramla O Awais; Ami Desai; Anthony Habgood; Steve Ludbrook; Andy D Blanchard; Alan C Perkins; R Gisli Jenkins; John F Marshall Journal: J Nucl Med Date: 2013-10-28 Impact factor: 10.057
Authors: Nimali P Withana; Xiaowei Ma; Helen M McGuire; Martijn Verdoes; Wouter A van der Linden; Leslie O Ofori; Ruiping Zhang; Hao Li; Laura E Sanman; Ke Wei; Shaobo Yao; Peilin Wu; Fang Li; Hui Huang; Zuojun Xu; Paul J Wolters; Glenn D Rosen; Harold R Collard; Zhaohui Zhu; Zhen Cheng; Matthew Bogyo Journal: Sci Rep Date: 2016-01-22 Impact factor: 4.379
Authors: Jessica Wahsner; Pauline Désogère; Eric Abston; Katherine A Graham-O'Regan; Junfeng Wang; Nicholas J Rotile; Markus D Schirmer; Diêgo Dos Santos Ferreira; Jingyi Sui; Bryan C Fuchs; Michael Lanuti; Peter Caravan Journal: J Am Chem Soc Date: 2019-03-27 Impact factor: 15.419
Authors: Zachary T Rosenkrans; Christopher F Massey; Ksenija Bernau; Carolina A Ferreira; Justin J Jeffery; Jefree J Schulte; Melissa Moore; Frank Valla; Jeanine M Batterton; Christopher R Drake; Alan B McMillan; Nathan Sandbo; Ali Pirasteh; Reinier Hernandez Journal: Eur J Nucl Med Mol Imaging Date: 2022-05-12 Impact factor: 10.057
Authors: Eman A Akam; Eric Abston; Nicholas J Rotile; Hannah R Slattery; Iris Y Zhou; Michael Lanuti; Peter Caravan Journal: Chem Sci Date: 2019-11-08 Impact factor: 9.825